Home

Johnson & Johnson (JNJ)

152.87
+1.72 (1.14%)

Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products

The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world.

SummaryNewsPress ReleasesChartHistoricalFAQ
Johnson & Johnson's Options Frenzy: What You Need to Knowbenzinga.com
Via Benzinga · January 30, 2025
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Ordersbenzinga.com
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.
Via Benzinga · January 29, 2025
Starbucks To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Wednesdaybenzinga.com
Via Benzinga · January 29, 2025
Marjorie Taylor Greene Loads Up On Meta, Amazon, Tesla, Nvidia And Other Stocks As Donald Trump's New Equations With Big Tech Leaders Sets Stage For Growth: What Is At Stake?benzinga.com
U.S. House Representative Marjorie Taylor Greene has disclosed new trades as Donald Trump's equations evolves with Big Tech leaders.
Via Benzinga · January 29, 2025
Where Johnson & Johnson Stands With Analystsbenzinga.com
Via Benzinga · January 23, 2025
Georgia Rep. Marjorie Taylor Greene Bought Up to $45K Worth of Johnson & Johnson Stockbenzinga.com
Via Benzinga · January 28, 2025
3 Stocks Upgraded by Bank of America – Here's Why They're Bullish
Bank of America analysts have recently shifted their views on these three stocks, leaving investors with a few points to consider.
Via MarketBeat · January 28, 2025
McDonald's To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesdaybenzinga.com
Via Benzinga · January 28, 2025
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · January 27, 2025
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024fool.com
Via The Motley Fool · January 25, 2025
Why Traders Are Buying the Dip on Johnson & Johnson Stock
Shares of Johnson & Johnson stock have declined by 11.5% in the quarter, and markets are calling for a bottom and rally here.
Via MarketBeat · January 25, 2025
5 of the Safest High-Yield Dividend Stocks You Can Confidently Buy for 2025fool.com
Five magnificent income stocks -- sporting an average yield of 4.26% -- can pad investors' pocketbooks in the new year (and well beyond).
Via The Motley Fool · January 24, 2025
Up About 62% in a Year, Can Intuitive Surgical Stock Keep Soaring?fool.com
Via The Motley Fool · January 23, 2025
Stocks Going Ex Dividend In February 2025talkmarkets.com
This article features a short list of some of the many stocks going ex-dividend during the next month, which can be helpful for traders and investors
Via Talk Markets · January 24, 2025
Abbott Laboratories Will Outperform Healthcare Stocks in 2025
Johnson & Johnson and Abbott Laboratories offer substantial opportunities for investors, but one is a better buy for total returns in 2025 and 2026.
Via MarketBeat · January 24, 2025
This Is 1 of the Healthiest High-Yielding Dividend Stocks You'll Findfool.com
Via The Motley Fool · January 23, 2025
Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analystbenzinga.com
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Via Benzinga · January 23, 2025
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcriptfool.com
JNJ earnings call for the period ending December 31, 2024.
Via The Motley Fool · January 22, 2025
Earnings Picture Remains Strong: A Closer Looktalkmarkets.com
Total earnings for the 62 S&P 500 companies that have reported results are up +19.6% from the same period last year on +8.4% higher revenues, with 82.3% beating EPS estimates and 69.4% beating revenue estimates.
Via Talk Markets · January 22, 2025
Johnson & Johnson Tops Q4 EPS Forecastsfool.com
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
Via The Motley Fool · January 22, 2025
J&J Stock Dips As 2025 Sales Guidance Misses Estimate, But Retail Mood Resilientstocktwits.com
During the earnings call, J&J highlighted several growth drivers, including its positioning for 5%-7% annual growth through 2030 and plans to increase its dividend annually.
Via Stocktwits · January 22, 2025
Johnson & Johnson Q4 Earnings And Revenues Top Estimatestalkmarkets.com
Johnson & Johnson came out with quarterly earnings of $2.04 per share.
Via Talk Markets · January 22, 2025
Johnson & Johnson Earnings Narrowly Top But Dow Giant's Sales Guidance Lightinvestors.com
The Dow Jones stock fell slightly early Wednesday.
Via Investor's Business Daily · January 22, 2025
S&P 500 Hits Fresh Records At 6,100: Strong Earnings, Trump's AI Wager Fuel Bull Runbenzinga.com
Market surges on AI Stargate initiative & strong earnings. S&P 500 hits record high of 6,100 points, led by tech giants & semiconductor stocks.
Via Benzinga · January 22, 2025
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analystbenzinga.com
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.
Via Benzinga · January 22, 2025